FOXA1 preserves cell polarity and restrains lysosome biogenesis in non-small cell lung adenocarcinoma

This study demonstrates that the transcription factor FOXA1 maintains epithelial cell polarity and suppresses lysosome biogenesis in non-small cell lung adenocarcinoma by competing with TFE3 at enhancers, thereby revealing a novel FOXA1-TFE3-lysosome axis as a potential therapeutic target to inhibit tumor plasticity and progression.

The Gist

The Big Picture: The "Foreman" of the Cell Construction Site

Imagine a lung cell as a tiny construction worker on a massive building site (the lung). For the building to stand tall and function correctly, these workers need to be organized, stand in neat rows, and hold hands with their neighbors. This organized state is called epithelial polarity.

However, cancer is like a chaotic construction site where workers stop holding hands, start running wild, and the building begins to crumble. This chaos is often driven by a process called EMT (Epithelial-Mesenchymal Transition), where organized cells turn into wandering, aggressive cells.

This study discovers a specific "Foreman" protein called FOXA1. Its main job is to keep the construction workers organized, stop them from going rogue, and manage the cell's internal trash disposal system (lysosomes).

---

1. The Foreman (FOXA1) Keeps Order

In healthy, organized lung cancer cells (the early stages), FOXA1 is the boss. It is highly active and sits on the DNA, shouting instructions that tell the cell: "Stay in your lane! Hold hands with your neighbor (CDH1)! Keep your shape!"

• The Analogy: Think of FOXA1 as the site manager with a clipboard. As long as the manager is present, the workers (cells) stay in their neat rows, and the building (tumor) grows in a controlled, organized way.
• The Finding: When the researchers looked at lung cancer cells, they found that FOXA1 was strongest in the cells that still looked like normal, organized lung tissue.

2. What Happens When the Foreman Leaves? (The Chaos)

The researchers decided to see what happens if they "fired" the foreman (by reducing FOXA1 levels). The results were dramatic:

• Loss of Structure: Without FOXA1, the cells stopped holding hands. They lost their neat shape and started looking like wandering, messy cells (mesenchymal cells).
• The "Trash" Pile-Up: This is the most surprising discovery. Inside the cells, there are tiny garbage trucks called lysosomes. Their job is to break down waste and recycle it.
  • In normal cells, these trucks are efficient and keep the site clean.
  • When FOXA1 was removed, the cells started building too many garbage trucks, but they couldn't get rid of the trash. The trucks just piled up in the cell, clogging the system.
  • The Analogy: Imagine a factory where the manager tells the recycling crew to stop working. Suddenly, the factory floor is flooded with half-empty recycling bins that no one is emptying. The factory becomes clogged and inefficient.

3. The Rivalry: The Foreman vs. The "Trash Manager"

How does FOXA1 stop the trash trucks from piling up? The study found a fascinating battle happening inside the cell's control room (the nucleus).

• The Rival: There is another protein called TFE3. TFE3 is like a hyper-active "Trash Manager" who loves to build more garbage trucks (lysosomes).
• The Battle: In healthy, organized cells, FOXA1 (the Foreman) stands in front of the "Trash Manager's" office door and blocks him. FOXA1 physically pushes TFE3 away, saying, "No, we don't need more trash trucks right now!"
• The Result: When FOXA1 is present, TFE3 is quiet, and the cell has just the right amount of lysosomes. When FOXA1 is gone, TFE3 takes over, orders a massive construction of lysosomes, and the cell gets clogged.

4. Why Does This Matter for Cancer?

You might think, "If the cells are clogged and messy, maybe the cancer stops?" Surprisingly, the opposite happened in the mouse models.

• The Twist: While the cells lost their organized shape, they actually became more dangerous in a specific way. They became more aggressive, started signaling to the immune system in confusing ways, and showed signs of being "stressed out" (senescence).
• The Tumor Microenvironment: The loss of FOXA1 changed the neighborhood around the tumor. It attracted different types of immune cells and changed how the tumor talked to its surroundings, making the environment more chaotic.

5. The Takeaway for Patients

This study gives us two major clues for fighting lung cancer:

1. A New Compass: FOXA1 can be used as a marker to tell doctors how "organized" a tumor is. High FOXA1 means the tumor is still somewhat organized (better prognosis). Low FOXA1 means the tumor is losing its structure and becoming more chaotic (worse prognosis).
2. A New Target: Since FOXA1 fights against TFE3 to stop the lysosome pile-up, maybe we can design drugs that mimic FOXA1. If we can force the "Trash Manager" (TFE3) to stop building so many garbage trucks, we might be able to stop the cancer cells from becoming so aggressive and messy.

Summary in One Sentence

FOXA1 is the strict site manager of lung cancer cells; when it's present, the cells stay organized and clean, but when it's gone, a rival manager (TFE3) takes over, clogging the cells with trash trucks and making the cancer more chaotic and dangerous.

Technical Summary

1. Problem Statement

Lung adenocarcinoma (LUAD) is characterized by high cellular plasticity, often driven by the Epithelial-Mesenchymal Transition (EMT). While the role of the pioneer transcription factor FOXA1 in lung development and differentiation is known, its specific function in maintaining epithelial polarity and restraining plasticity in established LUAD remains unclear. Furthermore, the relationship between cell identity regulators (like FOXA1) and organelle homeostasis, specifically lysosome biogenesis, has not been well established. The study aims to:

• Determine how partial loss of FOXA1 affects LUAD cell plasticity and progression.
• Elucidate the transcriptional circuitry linking polarity defects to lysosome homeostasis.
• Investigate the mechanism by which FOXA1 regulates the CLEAR (Coordinated Lysosomal Expression and Regulation) gene network.

2. Methodology

The study employed a comprehensive multi-omics and multi-model approach:

• Cell Line Models:
  • A549 LUAD cells: Treated with TGF-β (to induce mesenchymal state) or a newly synthesized TGF-β receptor inhibitor, B1.14 (to induce/maintain epithelial state).
  • Genetic Manipulation: Inducible shRNA-mediated knockdown (KD) of FOXA1 in A549, RERFLCMS (human), and LA795 (mouse) cell lines using a Tet-on system.
  • Functional Assays: 3D organoid culture, Transwell invasion/migration, cell cycle analysis (PI staining), senescence assays (β-galactosidase), and Seahorse metabolic profiling (glycolysis/mitochondrial stress).
• Genetically Engineered Mouse Models (GEMM):
  • KrasG12D; FOXA1+/+ (Control) vs. KrasG12D; FOXA1fl/+ (FOXA1-KD): Spontaneous lung tumors were induced in AT2 cells using Sftpc-Cre AAV9.
  • Tail Vein Injection: NCG mice injected with shFOXA1 or shNC A549 cells to assess tumorigenicity.
• Multi-Omics Profiling:
  • ATAC-seq & CUT&Tag: To map chromatin accessibility and transcription factor binding (FOXA1, H3K27ac, TFE3).
  • Bulk RNA-seq: To profile gene expression changes across EMT states and KD conditions.
  • Spatial Transcriptomics (Visium HD): High-resolution mapping of cell types, CNV (Copy Number Variation), and cell-cell communication in mouse tumors.
  • scRNA-seq Reference: Used for deconvolution of spatial data.
• Imaging & Histology:
  • Multiplex Immunohistochemistry (mIHC/TSA): To visualize co-localization of FOXA1, CDH1 (E-cadherin), TFE3, CTSB, CTSC, and TME markers.
  • Transmission Electron Microscopy (TEM): To visualize ultrastructural changes, specifically lysosome accumulation and cell junction integrity.

3. Key Contributions

• Discovery of a Novel FOXA1-Lysosome Axis: The paper establishes a direct mechanistic link between the transcription factor FOXA1 and the suppression of lysosome biogenesis in polarized LUAD cells.
• Competitive Binding Mechanism: It reveals that FOXA1 competes with the transcription factor TFE3 (a master regulator of lysosome biogenesis) for binding sites on the enhancers of lysosome-associated genes (specifically CTSB and CTSC).
• Polarity-Dependent Organelle Dynamics: It demonstrates that highly polarized, well-differentiated LUAD cells possess few lysosomes, whereas loss of polarity (via FOXA1 loss) triggers massive lysosome accumulation due to failed autophagic flux.
• New Therapeutic Target: It proposes the FOXA1–TFE3–lysosome axis as a potential therapeutic target to modulate tumor plasticity and aggressiveness.

4. Key Results

A. FOXA1 Maintains Epithelial Identity and Polarity

• Chromatin Occupancy: ATAC-seq and CUT&Tag showed FOXA1 binding is highest in epithelial-like A549 cells (treated with B1.14) and lowest in mesenchymal cells (TGF-β treated).
• In Vivo Validation: In KrasG12D mouse models, FOXA1 was highly expressed in polarized, CDH1-positive tumor cells. Heterozygous loss of FOXA1 (FOXA1-KD) led to:
  • Loss of apical-basal polarity and CDH1 expression.
  • Reduced organoid-forming efficiency (indicating loss of stemness/proliferative capacity).
  • Altered Tumor Microenvironment (TME): Reduced macrophage infiltration and altered cell-cell communication.
• Human Correlation: In human LUAD, FOXA1 expression correlates strongly with CDH1 and is high in well-differentiated (lepidic) regions but low in solid, poorly differentiated regions.

B. FOXA1 Loss Triggers Lysosome Accumulation

• Ultrastructural Changes: TEM revealed that FOXA1-KD cells (both in mouse models and human cell lines) accumulated large, lysosome-like organelles, whereas polarized FOXA1-high cells had few.
• Mechanism of Accumulation:
  • Upregulation of Biogenesis: FOXA1-KD led to the upregulation of the CLEAR gene network (e.g., CTSB, CTSC).
  • Downregulation of Fusion: FOXA1-KD caused significant downregulation of SNARE family genes (e.g., STX7, STX8, STX16, VAMP3), which are essential for vesicle fusion.
  • Result: Increased biogenesis combined with impaired fusion/autophagic flux (confirmed by P62 accumulation) led to lysosome "storage" rather than functional degradation.

C. The FOXA1–TFE3 Competitive Mechanism

• TFE3 Activation: FOXA1-KD resulted in increased nuclear TFE3 levels and enhanced TFE3 binding to lysosomal gene promoters.
• Competition: CUT&Tag analysis showed FOXA1 and TFE3 compete for binding at the enhancers of CTSB and CTSC.
  • High FOXA1 (Polarized): FOXA1 occupies the enhancer, repressing TFE3 binding and suppressing lysosome gene transcription.
  • Low FOXA1 (Mesenchymal): Loss of FOXA1 allows TFE3 to bind, driving the transcription of lysosomal genes and promoting biogenesis.
• TGF-β Signaling: FOXA1 loss also led to upregulated TGF-β signaling, creating a feedback loop that further promotes EMT and malignancy.

D. Functional Consequences

• Reduced Tumorigenicity: Despite increased malignancy markers (EMT score, CNV instability), FOXA1-KD cells showed reduced tumor formation in vivo and reduced organoid formation. This suggests that while FOXA1 loss induces a mesenchymal state, it simultaneously impairs the proliferative capacity required for robust tumor growth in this specific context.
• Metabolic Shift: FOXA1-KD cells showed increased oxidative phosphorylation and glycolysis stress.

5. Significance

• Biological Insight: This study redefines the role of FOXA1 not just as a lineage specifier, but as a critical "guardian" of epithelial polarity that actively suppresses lysosome biogenesis to maintain cellular homeostasis. It uncovers a previously unknown phenotype where polarized cancer cells have low lysosome content.
• Mechanistic Clarity: It provides a clear molecular mechanism (FOXA1 vs. TFE3 competition) explaining how cell identity dictates organelle dynamics.
• Clinical Implications:
  • Biomarker: FOXA1 expression levels could serve as a biomarker for tumor differentiation status and prognosis.
  • Therapeutic Strategy: Targeting the FOXA1–TFE3 axis or the downstream lysosome accumulation (e.g., via lysosome inhibitors or restoring FOXA1 function) could offer new avenues for treating aggressive, poorly differentiated LUAD.
  • EMT Reversal: Understanding how FOXA1 restrains EMT and TGF-β signaling suggests that maintaining FOXA1 levels could prevent tumor progression and metastasis.

In summary, the paper demonstrates that FOXA1 preserves epithelial polarity by directly repressing TFE3-mediated lysosome biogenesis, and the loss of this regulation drives a mesenchymal phenotype characterized by lysosome accumulation, impaired autophagy, and altered tumor microenvironment interactions.